SOUTH SAN FRANCISCO, Calif., Jan. 5, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 44th Annual J.P. Morgan Healthcare Conference. th44th Annual J.P. Morgan Healthcare ConferenceMonday, January 12, 2026, at 3:45 PM PT (6:45 PM ET) Presentation by Yujiro S. Hata, Chief Executive Officer, IDEAYA Biosciences, followed by analyst-hosted Q&A with Anupam Ra ...

Summary of IDEAYA Biosciences FY Conference Call Company Overview - **Company**: IDEAYA Biosciences (NasdaqGS:IDYA) - **Industry**: Precision medicine oncology Key Points Lead Program: Darovasertib - **Current Status**: In first-line registrational study for metastatic uveal melanoma - **Upcoming Milestones**: Randomized median progression-free survival (PFS) results expected by year-end 2025, with full enrollment for median overall survival (OS) component nearly complete, targeting over 450 patients [2][3][4] - **Breakthrough Therapy Designation**: Received for a phase 3 randomized neoadjuvant trial, which is now active with patients in screening [3][4] Patient Journey in Uveal Melanoma - **Lack of Approved Therapies**: No systemic approved therapies in neoadjuvant or adjuvant settings, with most metastatic patients also lacking approved options [5][6] - **Treatment Options**: Initial treatments include eye resection or plaque therapy, followed by adjuvant phase with no available therapies [7][8] Objectives for Neoadjuvant and Adjuvant Trials - **Primary Endpoint**: Eye preservation rate exceeding 10% with 95% confidence interval for the enucleation cohort [9][10] - **Visual Acuity Goals**: Aim for 20% or more patients in treatment arm passing a 15-letter BCVA vision test [10] DLL3 Topo ADC Program - **Efficacy Data**: Confirmed response rate of 70% in second-line small cell lung cancer at a dose of 2.4 mg/kg [15] - **Safety Profile**: Grade three or higher adverse events (AEs) below 20%, indicating potential for dose escalation [16] Future Development Plans - **Focus Areas**: Small cell lung cancer and neuroendocrine tumors (NETs) with plans to share more data in 2026 [20][23] - **MAT2A and MTAP Pathway**: Ongoing phase two trials for IDE397 (MAT2A inhibitor) and phase one for PRMT5 inhibitor, with updates expected in the first half of next year [24][25] Bispecific ADC Development - **B7-H3 and PTK7**: First-in-class bispecific ADC targeting co-expressed antigens in various tumor types, including non-small cell lung cancer and colorectal cancer [32][34] - **Patient Population**: Approximately one-third of lung cancer patients and 40%-50% of colorectal cancer patients are expected to express both antigens [34] Key Takeaways - **Upcoming Focus**: Randomized PFS results are critical for transitioning towards commercialization [38] - **Overall Strategy**: Emphasis on combination therapies and targeting co-alterations to enhance treatment efficacy [29][30] This summary encapsulates the essential insights from the IDEAYA Biosciences FY Conference Call, highlighting the company's strategic focus, ongoing clinical trials, and future development plans in the oncology sector.

Group 1 - Ideaya Biosciences, Inc. (IDYA) is a precision medicine oncology company that went public in May 2019, raising $57.5 million by issuing 5.75 million shares at $10 per share [1] - The current stock valuation of Ideaya Biosciences is $35 per share, indicating significant appreciation since its IPO [1] - The investing group Haggerston BioHealth, led by biotech consultant Edmund Ingham, provides insights and analysis on over 1,000 companies in the biotech, healthcare, and pharma sectors [1] Group 2 - Haggerston BioHealth offers catalysts for investors to monitor, along with buy and sell ratings, product sales forecasts, and integrated financial statements [1] - The group also conducts discounted cash flow analysis and market-by-market analysis for major pharmaceutical companies [1]

Core Insights - Ideaya Biosciences, Inc. (IDYA) is a precision medicine oncology company that went public in May 2019, raising $57.5 million by issuing 5.75 million shares at $10 per share, with the current stock valued at $35 per share [1] Group 1 - Ideaya Biosciences focuses on precision medicine within the oncology sector [1] - The company has been supported by a biotech consultant with over 5 years of experience in the biotech, healthcare, and pharma industries [1] - The investing group Haggerston BioHealth provides insights and forecasts for major pharmaceutical companies, including product sales and integrated financial statements [1]

Group 1 - IDEAYA Biosciences, Inc. is participating in several upcoming investor relations events, including the Cantor Global Healthcare Conference on September 3, 2025, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025 [1][2] - The company will host an R&D Day on September 8, 2025, to share clinical data updates, outline upcoming catalysts, and review its long-term portfolio strategy [1][6] - Key opinion leader Dr. Arun D. Singh will participate in the R&D Day, providing insights alongside the company's leadership team [6] Group 2 - IDEAYA is focused on precision medicine in oncology, aiming to discover and develop targeted therapies for cancer [3] - The company integrates small-molecule drug discovery, structural biology, and bioinformatics to develop tailored therapies aligned with genetic disease drivers [3] - IDEAYA has a pipeline that includes product candidates focused on synthetic lethality and antibody-drug conjugates for molecularly defined solid tumor indications [3]